The cancer testis antigen PRAME as a biomarker for solid tumor cancer management

Biomarkers in Medicine

Volumn 6, Issue 5, 2012, Pages 629-632

  Goodison, Steve ^a   Urquidi, Virginia ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

breast cancer; cancer testis antigen; leukemia; PRAME

Indexed keywords

CANCER TESTIS ANTIGEN; MESSENGER RNA; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; RETINOIC ACID; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHROMOSOME 22; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EDITORIAL; GENE; GENE EXPRESSION; HUMAN; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA GENE; RECURRENCE FREE SURVIVAL; SOLID TUMOR;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867635352     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.65     Document Type: Editorial

References (23)

1. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122(6), 835-847 (2005). (Pubitemid 41345202)
2. Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol. Cancer 9, 226 (2010).
3. Oehler VG, Guthrie KA, Cummings CL et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114(15), 3299-3308 (2009).
4. Santamaria C, Chillon MC, Garcia-Sanz R et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica 93(12), 1797-1805 (2008).
5. Dyrskjot L, Zieger K, Kissow Lildal T et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br. J. Cancer 107(1), 116-122 (2012).
6. Brenne K, Nymoen DA, Reich R, Davidson B. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am. J. Clin. Pathol. 137(2), 240-247 (2012).
7. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin. Cancer Res. 10(13), 4307-4313 (2004). (Pubitemid 38878868)
8. Van 'T Veer LJ, Dai H, Van De Vijver MJ et al. Gene expression profling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002). (Pubitemid 34130608)
9. Van De Vijver MJ, He YD, Van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002). (Pubitemid 35461656)
10. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003). (Pubitemid 36842560)
11. Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics 23(1), 30-37 (2007). (Pubitemid 46017852)
12. Sun Y, Urquidi V, Goodison S. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res. Treat. 119(3), 593-599 (2010).
13. Sun Y, Todorovic S, Goodison S. Local-learning-based feature selection for high-dimensional data analysis. IEEE Trans. Pattern Anal. Mach. Intell. 32(9), 1610-1626 (2010).
14. Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br. J. Cancer 99(3), 398-403 (2008).
15. Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res. Treat. 109(2), 359-365 (2008). (Pubitemid 351644842)
16. Schenk T, Stengel S, Goellner S, Steinbach D, Saluz HP. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46(9), 796-804 (2007). (Pubitemid 47106183)
17. Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk. Res. 35(9), 1219-1225 (2011).
18. Costessi A, Mahrour N, Tijchon E et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J. 30(18), 3786-3798 (2011).
19. De Carvalho DD, Binato R, Pereira WO et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 30(2), 223-233 (2011).
20. Rezvani K, Yong AS, Tawab A et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specifc peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113(10), 2245-2255 (2009).
21. Griffoen M, Kessler JH, Borghi M et al. Detection and functional analysis of CD8+ T cells specifc for PRAME: a target for T-cell therapy. Clin. Cancer Res. 12(10), 3130-3136 (2006). (Pubitemid 43837361)
22. Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modifcation of tumorantigen presenting cells and T-lymphocyte transfer. Blood 110(8), 2838-2845 (2007). (Pubitemid 350006936)
23. Quintarelli C, Dotti G, Hasan ST et al. High-avidity cytotoxic T lymphocytes specifc for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 117(12), 3353-3362 (2011).